Shc proteins participate in a variety of processes regulating cell proliferation, survival and apoptosis. The two ubiquitously expressed isoforms, p52Shc/p46Shc, couple tyrosine kinase receptors to Ras by recruiting Grb2/Sos complexes to a membrane-proximal localization. Tyrosine residues 239/240 and 317 become phosphorylated following receptor engagement and, as such, form two Grb2 binding sites, which have been proposed to be differentially coupled to Myc-dependent survival and to fos-dependent proliferation, respectively. Here, we have addressed the individual function of YY239/240 and Y317 in T-cell antigen receptor (TCR) signaling. We show that p52Shc is phosphorylated on both YY239/240 and Y317 following TCR engagement. Mutation of either YY239/ 240 or Y317 results in impaired interaction with Grb2 and inhibition of Ras/MAP kinase activation and CD69 induction, supporting a role for both Grb2 binding sites in this function. Substitution of either YY239/240 or Y317 also results in a defective activation of Rac and the coupled stress kinases JNK and p38. Furthermore, mutation of Y317 or, to a larger extent, of YY239/240, results in increased activation-induced cell death, which in cells expressing the FF239/240 mutant is accompanied by impaired TCR-dependent c-myc transcription. The data underline a pleiotropic and nonredundant role of Shc, mediated by both YY239/240 and Y317, in T-cell activation and survival.
Introduction
Initially identified as adaptors coupling receptor tyrosine kinases to Ras, Shc proteins have been implicated in a variety of pathways controlling cellular responses to extracellular stimuli (Ravichandran, 2001) . Shc is expressed as three isoforms encoded by the same locus, of which the two shortest, p52Shc and p46Shc, are ubiquitous and derive from alternative usage of two initiation codons (Migliaccio et al., 1997) . Expression of the longest isoform, p66Shc, is instead restricted and controlled by an alternative promoter (Ventura et al., 2002) . All three isoforms share a domain structure characterized by a C-terminal SH2 domain, a central proline-rich CH1 region, and an N-terminal PTB domain. The latter mediates interactions both with tyrosine-phosphorylated proteins and with membrane phospholipids (Zhou et al., 1995; Ravichandran et al., 1997) . The CH1 domain has three tyrosine residues, 239/ 240 and 317 in human p52Shc, which upon phosphorylation interact with Grb2 (Salcini et al., 1994; Gotoh et al., 1996; van der Geer et al., 1996) . These residues have been proposed to differentially couple Shc to fosdependent mitogenesis (Y317) and to Myc-dependent survival pathways (YY239/240) (Gotoh et al., 1996) . p66Shc has an additional N-terminal CH domain, which controls apoptotic responses to oxidative stress (Migliaccio et al., 1999) . Additional, albeit not fully characterized functions of Shc include coupling growth factor receptors to reorganization of the actin cytoskeleton and to endocytosis (Thomas et al., 1995; Lotti et al., 1996; Gu et al., 1999; Sakaguchi et al., 2001) .
Although p66Shc expression can be detected in T cells following apoptogenic stimulation (Pacini et al., 2004) , p52/p46Shc are the major isoforms in T cells. Following T-cell antigen receptor (TCR) engagement, Shc is recruited to the TCR through both a PTB domainmediated interaction with ZAP-70 and an SH2 domainmediated interaction with CD3z (Ravichandran et al., 1993; Milia et al., 1996) . Once bound to the TCR, Shc becomes phosphorylated on tyrosine residues and, as such, not only recruits Grb2/Sos complexes but also enhances Grb2/Sos association . Furthermore, Shc inducibly associates with lipid rafts (Plyte et al., 2000) , supporting the notion that Shc participates in the supramolecular signaling complex assembled in this location following TCR engagement (Langlet et al., 2000) . Although many of the signaling molecules that are recruited to the TCR-associated signalosome interact with Grb2/Sos and are implicated in Ras activation, a number of data support a nonredundant role for Shc in TCR signaling to Ras (Milia et al., 1996; Pratt et al., 1999; Plyte et al., 2000; Iwashima et al., 2002; Zhang et al., 2002) . In addition, Shc has been proposed to participate in activationinduced cell death (AICD) (Pratt et al., 1999) , as well as in the negative control of TCR-dependent signaling as the result of its capacity to recruit the lipid phosphatase SHIP-1 (Lamkin et al., 1997) .
Here, we dissect the role of the individual Grb2 binding sites in TCR signaling to Ras and address the potential involvement of Shc in other cellular functions. The results support a nonredundant role of Shc in Ras/ MAP kinase (MAPK) activation, which appears mediated by both Grb2 binding sites. Furthermore, we show that YY239/240 and Y317 couple Shc to TCRdependent Rac and stress-kinase activation, but not to TCR internalization. Finally, we present evidence that YY239/240 and Y317 are required for activation by the TCR of Myc-dependent and -independent survival pathways. The data highlight a pleiotropic role of Shc in TCR signaling.
Results

p52Shc controls Ras/MAPK activation through both Grb2 binding sites
Following TCR engagement, p52Shc phosphorylation on YY239/240 and Y317 by ZAP-70 and Lck results in the generation of two Grb2 docking sites (Pacini et al., 1998; Walk et al., 1998) . To dissect their individual function, we generated stable Jurkat T-cell transfectants using expression vectors encoding wild-type p52Shc or mutants carrying Tyr-Phe substitutions at positions 239/240 (2F) or 317 (1F) (Figure 1a ). p52Shc proteins were N-terminally tagged with an influenza virus hemagglutinin epitope (HA) (Figure 1b ). All transfectants expressed levels of recombinant Shc comparable to those of endogenous Shc (Figure1b and data not shown), with the exception of Shc2F-expressing cells, where the levels of Shc2F were slightly lower compared to the other cell lines. All transfectants expressed comparable levels of surface TCR/CD3 (data not shown). Tyrosine phosphorylation of HA-p52Shc and of the 1F/2F mutants was analysed by immunoblot analysis of HA-specific immunoprecipitates with antiphosphotyrosine antibodies. All HA-Shc proteins were phosphorylated, although the levels of phosphorylation of Shc1F and Shc2F were reduced compared to wildtype p52Shc (Figure 1c) . Furthermore, all HA-Shc proteins associated with ZAP-70 ( Figure 1c ). This association was consistently enhanced in the case of Shc2F, suggesting that the conformation of this mutant may favor or stabilize its association with ZAP-70.
The effect of ablation of the individual Grb2 binding sites on p52Shc association with Grb2 was investigated. Both Shc1F and Shc2F showed a defective association with Grb2 following TCR engagement (Figure 2a and c), which was more pronounced when p52Shc was mutated on YY239/240. The capacity of phosphorylated Shc, HA-tagged p52Shc; Shc1F, Y317F HA-tagged p52Shc; Shc2F, HA-tagged YY239/240FF p52Shc. Shc2F expression was B70% compared to Shc/Shc1F. (c) Top, immunoblot analysis using antiphosphotyrosine mAb of HA-specific immunoprecipitates from Jurkat T-cell transfectants expressing wild-type or mutant p52Shc. Cells were nonactivated (0) or activated by TCR/CD3 crosslinking for 5 min with anti-CD3 mAb (CD3). The filter was reprobed after stripping with anti-Shc (middle) and anti-ZAP-70 (bottom) mAb. Representative experiments are shown (nX3) Analysis of the p52Shc Grb2 docking sites in TCR signaling L Patrussi et al YY239/240 and Y317 to interact with Grb2 was also tested in in vitro binding assays using GST fusions containing the isolated CH1 domain, as such, or mutated on YY239/240 or Y317, after in vitro phosphorylation with recombinant ZAP-70. The in vitro association of Grb2 with the phosphorylated CH1 domain was equally impaired when either of two Grb2 binding sites was ablated (Figure 2b and c) . Collectively, the data suggest that, while YY239/240 may associate with Grb2 with a higher stoichiometry in vivo, both YY239/240 and Y317 participate in Grb2/Sos recruitment following TCR engagement.
The effect of the YY239/240 or Y317 mutations on TCR-dependent Ras activation was tested by in vitro binding assays, using a GST-Raf fusion, which selectively interacts with GTP-bound Ras. Immunoblot analysis with anti-Ras antibodies of the proteins pulled down by GST-Raf showed that mutation of either Grb2 binding site results in attenuation of TCR-dependent Ras activation (Figure 3a (Figure 4) , was observed when TCR engagement was bypassed using PMA, underlining the integrity of the Ras/MAPK pathway in all transfectants. Furthermore, no differences in phosphorylation of LAT, one of the principal mediators of signaling to Ras/MAPK in T cells, nor in its association with Grb2, were detected (data not shown). The data indicate that Shc1F and Shc2F transdominantly inhibit endogenous Shc, resulting in impaired Grb2/Sos recruitment and defective coupling of the TCR to Ras and MAPKs.
No effect of Shc mutation was observed on the Ca 2 þ / calcineurin pathway, the other principal pathway coupling the TCR to gene expression. Indeed, flow cytometric analysis showed that Ca 2 þ mobilization was unaffected in cells expressing Shc1F or Shc2F (Figure 5a ). In addition, confocal microscopy of cells transfected with GFP-tagged NFAT showed that TCR engagement effectively triggered nuclear translocation of NFAT, which is exquisitely dependent on Ca 2 þ mobilization, in all cell lines (Figure 5b) . Collectively, the data support a nonredundant and selective role of p52Shc in TCR signaling to Ras/MAPK mediated by both Grb2 binding sites. Besides associating with Sos, Grb2 is known to interact with alternative molecular partners. Among these are the regulatory p85 subunit of PI-3 kinase (PI-3K), the SLP-76 and Gab adaptors and the guanine nucleotide exchanger, Vav (Koretzky, 1997) . These proteins are implicated, directly or indirectly, in the activation of Rho GTPases and as such contribute to the regulation of the actin cytoskeleton dynamics (Bustelo, 2000) . In addition, Sos itself displays guanine nucleotide exchange activity on Rac (Nimnual et al., 1998) . Furthermore, Ras is required for Rho family GTPase activation in T cells (Cantrell, 2003) . Hence, Shc can potentially participate in the regulation of Rho GTPases as the result of Grb2 recruitment and initiation of Rasdependent and -independent downstream pathways.
To address the potential role of p52Shc in TCRdependent Rac activation, pull-down assays were carried out using a GST-Pak1 fusion, which interacts preferentially with GTP-bound Rac/Cdc42. Immunoblot analysis with anti-Rac antibodies of the proteins bound to GST-Pak1 showed that TCR-dependent Rac activation was impaired in cells expressing Shc1F or Shc2F ( Figure 6a ). This inhibitory effect on Rac activation was particularly evident in cells expressing Shc2F. Activation of Rho GTPases in hemopoietic cells is promoted by the guanine nucleotide exchanger, Vav. Following TCR engagement, Vav is recruited to LATbound SLP-76 in a membrane-proximal localization, where it is phosphorylated by Src and Syk kinases (Bustelo, 2000) . To understand whether the impairment in Rac and stress-kinase activation correlates with a reduction in Vav activation, Vav-specific immunoprecipitates were assayed by immunoblot with anti-phosphotyrosine antibodies. Ablation of either Grb2 binding site did not affect Vav phosphorylation (Figure 6b ), indicating that the reduction in TCR-dependent Rac activation is not accounted for by Vav.
Activation of Rac, besides promoting F-actin reorganization, also results in the activation of Pak1, which initiates a serine-threonine kinase cascade, leading to the activation of the stress-kinases p38 and JNK (Kyriakis and Avruch, 1996) . The effect of YY239/240 or Y317 substitution on stress-kinase activation was assessed by immunoblot analysis of cell lysates with phosphospecific antibodies. A dramatic reduction in TCR-dependent activation of both p38 (Figure 7a and c) and JNK (Figure 7b and c) was observed in cells expressing Shc1F or Shc2F. Hence, p52Shc plays a nonredundant role in the activation of Rac and stress kinases, and this function is mediated by both YY239/ 240 and Y317.
Neither Grb2 binding site of p52Shc is implicated in TCR downregulation
Engaged TCR is rapidly internalized by endocytosis, a process controlled by Rab GTPases (Somsel Rodman and Wandinger-Ness, 2000) . TCR downregulation results in degradation of the TCRab and signal termination (Alcover and Alarcon, 2000) . Furthermore, as engaged TCR complexes become internalized, new TCRs become engaged by the same peptide/MHC, resulting in sustained signaling (Valitutti and Lanzavecchia, 1997) . Inhibition of endocytosis results in defective T-cell activation (Alcover and Alarcon, 2000) .
Shc has been proposed to participate in receptormediated endocytosis. Colocalization of Shc with internalized EGFR in the endocytic compartment has indeed been observed (Lotti et al., 1996) . Furthermore, Shc has been shown to interact both with b-adaptin (Okabayashi et al., 1996) and with dynamin (Baron et al., 1998) , two proteins implicated in receptormediated endocytosis. Signaling from Ras to Rab has also been demonstrated (Macara et al., 1996) . Hence, Shc could participate in membrane trafficking both directly by interacting with b-adaptin and/or dynamin and indirectly by activating Ras. The effect of mutation of either Grb2 binding site of Shc on TCR internalization was addressed. Cells expressing HA-Shc or the 1F/2F mutants were incubated on ice with saturating amounts of fluorochromelabeled anti-CD3 mAb to achieve full TCR occupancy, and subsequently shifted to 371C for different lengths of time. Internalized TCR/anti-CD3 complexes were quantitated by flow cytometry after stripping the cells of surface-bound mAb. As shown in Figure 8 , the extent and time course of TCR internalization was comparable in all transfectants. Hence, while in T cells, Shc may participate in receptor-mediated endocytosis through alternative mechanisms, neither Grb2 binding site is implicated in this function.
Differential coupling of YY239/240 and Y317 to c-myc expression and cell survival While in B cells both Grb2 binding sites on Shc are required for efficient formation of Grb2/Sos complexes and Ras activation following BCR engagement (Harmer and DeFranco, 1997), a distinct function for YY239/240 has been proposed in IL-3-dependent pro-B cells. Specifically, expression of an Shc mutant lacking YY239/240 results in decreased c-myc expression in response to IL-3, which correlates with enhanced sensitivity to apoptotic stimuli, while leaving unaffected Erk activation (Gotoh et al., 1996) . Conversely, the same mutant expressed in a murine T-cell hybridoma has been shown to impair Erk activation and to protect cells from AICD (Pratt et al., 1999) . To further address the role of Shc in T-cell survival, the outcome of YY239/ 240 or Y317 ablation on TCR-dependent c-myc expression and AICD was investigated. A time-course analysis of c-myc transcription was carried out by semiquantitative RT-PCR. C-myc mRNA reached maximal levels 30 min after TCR/CD3 crosslinking and decreased at later time points in all transfectants (Figure 9a ). Overexpression of wild-type Shc enhanced c-myc expression. C-myc was expressed to a similar extent and with a similar kinetics in cells expressing Shc1F. Conversely, TCR/CD3-dependent c-myc transcription was completely abolished in the presence of Shc2F mutant. The reduction in c-myc transcription correlated with a significant increase in AICD of cells expressing Shc2F (Figure 9b and c) , suggesting that YY239/240 couple the TCR to Myc-dependent survival. Of note, expression of Shc1F, while not affecting c-myc transcription (Figure 9a ), also resulted in enhanced AICD, albeit to 
Discussion
TCR engagement results in the generation of multimolecular assemblies, many of which include Grb2 and have, therefore, the potential to activate Ras, raising the question of a potential redundancy in the pathways converging onto this GTPase. Furthermore, Ras is activated in T cells through an additional mechanism involving the RasGRP guanine nucleotide exchanger, which is recruited to the membrane through its interaction with diacylglycerol (Ebinu et al., 1998) . On the other hand, the key role of Ras in controlling mitogenic responses suggests that a threshold of active Ras must be reached before cells commit to proliferation, and that all these pathways may be required to fine-tune the extent and duration of Ras activation. The reduction in TCR-dependent Ras and MAPK activation by Shc mutants lacking either of the two Grb2 binding sites strongly supports the latter hypothesis. It is worth noting that substitution of either YY239/240 or Y317 results in a similar reduction in Grb2 binding in vitro, while TCR-dependent Grb2 recruitment in the T-cell transfectants, as well as downstream events, are more severely affected by YY239/240 ablation, notwithstanding the lower levels of Shc2F expression compared to Shc1F. While these data suggest a predominant role for YY239/240 in Grb2 recruitment in response to TCR engagement, the significant impairment of Ras/MAPK and stress-kinase activation in cells expressing Shc1F indicates that both Grb2 binding sites contribute to this function. By analogy with B cells, binding of Grb2 to both phosphorylated YY239/240 and Y317 may be , 1997) . This result is at variance with a report supporting a virtually exclusive role of YY239/240 in MAPK activation and IL-2 expression (Pratt et al., 1999) . The different experimental settings (murine T-cell hybridoma versus Jurkat cells, GST versus HA tag) might account for the observed differences. Nevertheless, while YY239/240 have been proposed to couple the IL-3R to a Ras/ MAPK-independent survival pathway in pro-B cells (Gotoh et al., 1996) , our data, in agreement with the report by Pratt et al. (1999) , show that in T cells this Grb2 binding site is essential for coupling the TCR to Ras/MAPK signaling. Shc has been implicated in transducing survival signals triggered by many surface receptors (Atwal et al., 2000; Besset et al., 2000; Gu et al., 2000; Matter and Ruoslahti, 2001; Pelicci et al., 2002; Nelson et al., 2003) . Although the mechanisms underlying this activity are not fully understood, the dual capacity of Shc to transduce both mitogenic and survival signals appears dependent on Grb2 recruitment and its subsequent interaction with different molecular partners. Rasdependent mitogenic signaling is triggered when Grb2 is bound to Sos. Alternatively Grb2 can interact, directly or through Gab2, with p85 PI-3K, resulting in the initiation of survival pathways involving c-myc expression and upregulation of bcl-2 (Atwal et al., 2000; Besset et al., 2000; Matter and Ruoslahti, 2001; Pelicci et al., 2002; Nelson et al., 2003) . In lymphocytes, Myc is expressed as an early response gene and plays a pleiotropic role in cell cycle progression, survival and apoptosis. Expression in pro-B cells of an Shc mutant lacking Y240, but not of a mutant lacking Y317, results in enhanced sensitivity to IL-3 withdrawal and serum starvation, which correlates with a reduction in IL-3-dependent c-myc expression (Gotoh et al., 1996) . Together with our finding that expression of Shc2F results in increased T-cell susceptibility to AICD, which correlates with a decrease in the levels of c-myc induction, these data support a role for Shc, mediated by YY239/240, in c-myc expression and lymphocyte survival. Whether the pathway that controls Shcdependent regulation of c-myc expression involves PI-3K remains to be determined. Of note, albeit to a lesser extent, mutation of Y317 also enhances AICD, but does not impair c-myc expression, suggesting that Myc is not sufficient to ensure T-cell survival and that Shc may be implicated in additional, Myc-independent survival pathways. One of these may be controlled by the Ras/ MAPK pathway, which has been shown to protect hematopoietic cells from apoptotic death (Kinoshita et al., 1995) and is severely impaired in T cells expressing Shc1F or Shc2F. In this context, the requirement for low-level signaling by the TCR in quiescent T cells as a means of survival, which involves signaling through Erk (Roose et al., 2003) , may explain the increased basal levels of death of cells expressing Shc1F or Shc2F. Our data are at variance with the protective effects from AICD of a mutant lacking Y240 in a murine T-cell hybridoma (Pratt et al., 1999) . The authors show that this effect is dependent on inhibition of FasL gene expression by F240Shc. The different requirement for AP-1, which is controlled by the Ras/MAPK pathway, in the activation of FasL gene transcription in murine versus human T cells (Matsui et al., 2000) may explain this discrepancy.
TCR engagement, besides eliciting long-term effects, which depend on the activation of gene expression through the Ras/MAPK and Ca 2 þ /calcineurin pathways, also promotes transient alterations, including reorganization of cortical actin and receptor endocytosis, both of which is required for productive TCR signaling. F-actin reorganization is a key driving force in the formation of the immunological synapse between T cell and APC (Acuto and Cantrell, 2000) , and as such contributes to productive triggering of the TCR signaling cascade. On the other hand, TCR downregulation is essential both for sustained signaling and for signal termination (Alcover and Alarcon, 2000) . Our data uncover a role for Shc, dependent on both YY239/240 and Y317, in the activation of Rac, which in T cells is essential for F-actin reorganization (Acuto and Cantrell, 2000) . Expression of either mutant also results in a dramatic reduction in TCR-dependent activation of stress kinases, which have been identified as downstream effectors of Rac (Kyriakis and Avruch, 1996) . Although Shc2F affects more severely Rac activation, the reduction of p38 and JNK activation is comparable in cells expressing either Shc1F or Shc2F, suggesting that Shc may participate to additional pathways of stress-kinase activation. A requirement for Shc in JNK activation has been demonstrated in B cells (Hashimoto et al., 1999) . Furthermore, a constitutive Shc association with F-actin, which increases following NGFR stimulation, has been demonstrated in PC12 cells, suggesting a role for Shc in the reorganization of the actin cytoskeleton (Thomas et al., 1995) . Of note, as opposed to Rac, no effect of YY239/240 or Y317 substitution was observed on tyrosine phosphorylation of Vav, the principal Rho GTPase exchanger in T-cells. An alternative mechanism might involve activation of PI-3K, which controls Rho GTPase-dependent changes in the actin cytoskeleton (Fruman and Cantley, 2002) . Although Vav activation is controlled in part by its recruitment to the membrane through an interaction involving its PH domain and membrane PI(3,4,5)P3, recent evidence supports a role for PI-3K downstream of Vav in Rac activation (Reynolds et al., 2002) . PI-3K activation might be achieved either as the result of p85 PI-3K recruitment by Grb2 or Gab2 (Besset et al., 2000; Gu et al., 2000) , or through Ras (Cantrell, 2003) . Alternatively, the dual exchange activity of Sos on Ras and Rac (Nimnual et al., 1998) may underlie the coordinated activation of the two GTPases by Shc.
The implication of Shc in ligand-induced receptor endocytosis is as yet hypothetical. Immunoelectron microscopy of Shc localization in EGF-stimulated cells showed that Shc associates with endocytic structures, such as coated pits and endosomes (Lotti et al., 1996) . Furthermore, Shc interacts with b-adaptin, a component of the AP2 clathrin adaptor complex, through a sequence within the CH1 domain mapping to aminoacid residues 346-355 (Okabayashi et al., 1996) , as well as with dynamin, a 100 kDa GTPase implicated in receptor-mediated endocytosis (Baron et al., 1998) . This interaction is mediated by Shc-bound Grb2 (Baron et al., 1998) . Finally, signaling from Ras to Rab GTPases has been described (Macara et al., 1996) , which would link Ras activation to endocytosis. Our data show that, while Ras activity is inhibited by Shc1F and Shc2F, no significant effect is observed on TCR internalization, ruling out a major role for Shc-mediated Ras activation in the control of receptor endocytosis. Furthermore, alternative interactions involving Shc-bound Grb2, such as the association with dynamin, are unlikely to be implicated in this process. Whether Shc participates in TCR endocytosis through a mechanism involving alternative interactions remains to be determined.
Materials and methods
Cells, plasmids, antibodies and GST fusion proteins
The T-lymphoma Jurkat line was used for the generation of stable transfectants. The cDNA encoding HA-tagged p52Shc (a gift of T Pawson) was cloned into pcDNA3 (Invitrogen srl, Milan, Italy). The 1F (Y317F) and 2F (YY239/240FF) mutants were generated by M13-based, oligonucleotidedirected site-specific mutagenesis using standard procedures. A glutathione-Sepharose 4B-immobilized GST fusion containing the Shc CH1 domain was described previously (Salcini et al., 1994) . The portion of Shc cDNA encoding the CH1 domain was mutagenized to obtain 1F and 2F GST-CH1 proteins. Recombinant GST-ZAP-70 (Magistrelli et al., 1999) was purified on GSH-Sepharose (Amersham Biosciences Europe GmbH, Milan, Italy). Agarose-conjugated GST-Raf and GST-Pak1 was purchased from Upstate Biotechnology Inc. (Boston, MA, USA).
HA-Shc and mutants thereof were immunoprecipitated using a mouse IgG2a anti-HA mAb (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and protein A-Sepharose (Amersham Biosciences Europe GmbH) and probed by immunoblot using anti-HA mAb (Roche Diagnostics GmbH, Mannheim, Germany) or anti-Shc polyclonal antibodies (Upstate Biotechnology Inc.). Phosphospecific polyclonal antibodies against the active forms of Erk, MEK, p38 and JNK were purchased from Cell Signaling Technologies (Beverly, MA, USA). Anti-phosphotyrosine, anti-Ras, antiRac, anti-Grb2 and anti-ZAP-70 mAbs were purchased from Upstate Biotechnology Inc.; anti-actin mAb from Amersham Biosciences Europe GmbH; anti-Shc mAb from BD Biosciences (Heidelberg, Germany); anti-Erk, anti-p38, anti-Vav, andi-MEK and anti-Shc antibodies from Santa Cruz Biotechnology. IgG from OKT3 (anti-human CD3; ATCC) hybridoma supernatants were affinity-purified on Mabtrap (Amersham Pharmacia Italia srl) and titrated by flow cytometry. Fluorochrome-labeled annexin V and anti-human CD69 and CD3 mAb were purchased from BD Biosciences. Secondary unlabeled antibodies were from Cappel (Durham, NC, USA), and secondary peroxidase-labeled antibodies from Amersham Biosciences Europe GmbH.
Transfections, confocal microscopy and flow cytometry pcDNA3 or the pcDNA3-Shc expression constructs were introduced into Jurkat cells by electroporation and stably transfected cells were selected in medium containing 1 mg/ml G418 (Invitrogen srl, Milan, Italy). To avoid clonal differences, mixed populations resulting from bulk selection were used, with the exception of HA-Shc, whose expression levels were too low in the bulk transfectant. A representative clone (out of three with similar expression levels) was therefore used. Cells were transiently transfected with the plasmid pEGFP/NFAT-1D as described (Plyte et al., 2001) . CD3 was crosslinked for 30 min at 371C with anti-CD3 mAb and secondary antibodies. Confocal microscopy was carried out on a Leica Microsystems confocal microscope (Heidelberg, Germany).
CD3/CD69 surface expression on Jurkat transfectants was quantitated by flow cytometry using FITC-labeled mAb. Samples were processed using a FACScan flow cytometer (Becton-Dickinson, San Jose, CA, USA).
Calcium flux was measured using Fluo-4 FF (Molecular Probes Europe BV, Leiden, the Netherlands). Cells (10 6 / sample) were suspended in 200 ml RPMI w/o phenol Red (Invitrogen srl) added with 25 mM HEPES (pH 7.4), 5 mM Fluo-4 and 500 mM sulfinpyrazone (Sigma-Aldrich srl, Milan, Italy), incubated 45 min at 371C, pelleted by centrifugation and resuspended in 500 ml of the same medium without Fluo-4. Baseline fluorescence was recorded for 40 s at 371C. Cells were subsequently added with saturating amounts of anti-CD3 mAb and 50 mg/ml secondary antibody. Fluorescence was continuously recorded for 512 s at 371C. Receptor-independent calcium mobilization was determined using the calcium ionophore A23187 (500 ng/ml).
Activations, immunoprecipitations, in vitro binding assays and immunoblots
Activations by anti-CD3 crosslinking were carried out as described (Pacini et al., 2004) . Cells (1-5 Â 10 6 /sample for direct immunoblot analysis, 1-5 Â 10 7 /sample for immunoprecipitations or in vitro binding assays) were lysed in 1% (v/v) Triton X-100 in 20 mM Tris-HCl (pH 8), 150 mM NaCl (added with 0.2 mg/ml Na orthovanadate, 1 mg/ml pepstatin, leupeptin, aprotinin and 10 mM PMSF) and postnuclear supernatants were probed as such or immunoprecipitated using the appropriate antibodies and protein A-Sepharose (Amersham Biosciences Europe GmbH). For in vitro binding assays, cell lysis was carried out using 3% Triton X-100 to disrupt preexisting molecular interactions. Postnuclear supernatants were adjusted to 1% Triton X-100, precleared for 30 min at 41C with agarose-bound GST and subsequently incubated for 2 h at 41C with the agarose-bound GST fusion proteins. The preclearing step was omitted in the binding assays with GSTRaf and GST-Pak1 because of the very short half-life of Ras and Rac activity. The GST-CH1 fusion proteins were phosphorylated in vitro in 20 mM Tris-HCl (pH 7.4), 10 mM MgCl 2 , 10 mM MnCl 2 , 50 mM ATP for 20 min at 371C using 125 ng GST-ZAP-70/reaction. The effectiveness of phosphorylation was checked by immunoblot with anti-phosphotyrosine antibodies. Immunoblots were carried out using a chemiluminescence detection system (Pierce, Rockford, IL, USA). To analyse Shc interaction with Grb2, immunoprecipitates were resolved in nonreducing conditions. AICD was induced by prolonged CD3 crosslinking using OKT3 and plate-bound secondary antibodies in the absence of serum. Cell viability was assessed by Trypan blue exclusion. Apoptosis was measured by annexin V staining and TUNEL as described (Pacini et al., 2004) .
RT-PCR
Semiquantitative RT-PCR was carried out using total RNA extracted using the RNA WIZ TM isolation reagent (Ambion Inc., Austin, TX, USA). RT-PCR was carried out using AMV reverse transcriptase (Roche Diagnostics SpA, Milan, Italy) and the Expand High Fidelity PCR system from Roche Diagnostics SpA or Taq DNA polymerase from Promega Italia srl (Milan, Italy). The primer for first strand was oligodT (Promega Italia srl, Milan, Italy), while pairs of specific primers were used for cDNA amplification. Actin was used as housekeeping control. cDNA was amplified in an Eppendorf Mastercycler Thermal Cycler (Eppendorf srl, Milan, Italy). The RT-PCR products were separated by agarose gel electrophoresis, and the intensities of the c-myc and actinspecific bands was quantitated by laser densitometry (Kodak Digital Sciencet Electrophoresis Documentation and Analysis System 120). The relative levels of c-myc mRNA were normalized to the levels of actin mRNA.
TCR internalization
TCR internalization was quantitated as described (D'Oro et al., 2002) . Briefly, cells were incubated on ice with FITC-labeled anti-CD3 mAb for 30 min (time 0) and subsequently washed and transferred to 371C for 15 min-4 h. After stripping residual surface-bound mAb (10 s at room temperature in 100 mM glycine, 100 mM NaCl, pH 2.5), internalized mAb was quantitated by flow cytometry (ARF t , median acid-resistant fluorescence at time 't'). The levels of surface binding at time 0 were determined on a sample taken before transfer to 371C (SF, median specific fluorescence). The levels of autofluorescence at time 0 were quantitated by flow cytometry after stripping surface-bound antibody (AF, median aspecific fluorescence). Receptor internalization (SR t , % surface receptor internalized at time 't') was calculated as follows: % SR t ¼ 100 Â (ARF t ÀAF)/(SFÀAF).
